Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.25.1 (
proteasome
)
28,817
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Proteasome plays a key role in antigen presentation through MHC class I pathway. Thus, approaches are actively developed to increase
proteasome
targeting of DNA-vaccine encoded proteins. Gene of reverse transcriptase of HIV-1 is used in DNA-vaccines. It was shown, that revertase degraded in cells slowly (half-life is 18-20 h). Revertase content increased in presence of
proteasome
inhibitors MG132 and epoxomicin indicated that it degraded by
proteasome
. Level of protein was 2 fold higher after treatment with MG132 then after epoxomicin treatment. Since epoxomicin is more specific proteasome inhibitor it indicated that other cellular proteases can take part in revertase degradation. With the aim to increase affinity and degradation rate by
proteasome
of revertase we have to add strong degradation signal.
Ornithine decarboxylase
contains this kind of signals, it's unique properties are fast degradation by
proteasome
in ubiquitin-independent manner. As result fusion protein of revertase and
ornithine decarboxylase
was created. Half-life of fusion protein was 6 time less than revertase (3 h). Degradation of fusion protein was blocked by
proteasome
inhibitors 10 times stronger than revertase. Thus, degradation by
proteasome
pathway of reverse transcriptase was enhanced by fusion with
ornithine decarboxylase
. Performance of this fusion could improve presentation of revertase in DNA-vaccine.
...
PMID:[Artifitial increase of HIV-1 reverse transcriptase turnover through proteasome pathway]. 1720 25
Protein degradation mediated by the ubiquitin/
proteasome
system is the major route for the degradation of cellular proteins. In this pathway the ubiquitination of the target proteins is manifested via the concerted action of several enzymes. The ubiquinated proteins are then recognized and degraded by the 26S
proteasome
. There are few reports of proteins degraded by the 26S protesome without ubiquitination, with
ornithine decarboxylase
being the most notable representative of this group. Interestingly, while the degradation of ODC is independent of ubiquitination, the degradation of other enzymes of the polyamine biosynthesis pathway is ubiquitin dependent. The present review describes the degradation of enzymes and regulators of the polyamine biosynthesis pathway.
...
PMID:Ubiquitin dependent and independent protein degradation in the regulation of cellular polyamines. 1740 2
Mouse ODC (
ornithine decarboxylase
) is quickly degraded by the 26S
proteasome
in mammalian and fungal cells. Its degradation is independent of ubiquitin but requires a degradation signal composed of residues 425-461 at the ODC C-terminus, cODC (the last 37 amino acids of the ODC C-terminus). Mutational analysis of cODC revealed the presence of two essential elements in the degradation signal. The first consists of cysteine and alanine at residues 441 and 442 respectively. The second element is the C-terminus distal to residue 442; it has little or no sequence specificity, but is intolerant of insertions or deletions that alter its span. Reducing conditions, which preclude all well-characterized chemical reactions of the Cys(441) thiol, are essential for in vitro degradation. These experiments imply that the degradative function of Cys(441) does not involve its participation in chemical reaction; it, instead, functions within a structural element for recognition by the 26S
proteasome
.
...
PMID:Structural elements of the ubiquitin-independent proteasome degron of ornithine decarboxylase. 1797 31
Mammalian antizyme (mAz) is a central element of a feedback circuit regulating cellular polyamines by accelerating
ornithine decarboxylase
(
ODC
) degradation and inhibiting polyamine uptake. Although yeast antizyme (yAz) stimulates the degradation of yeast
ODC
(yODC), we show here that it has only a minor effect on polyamine uptake by yeast cells. A segment of yODC that parallels the Az binding segment of mammalian
ODC
(mODC) is required for its binding to yAz. Although demonstrating minimal homology to mAz, our results suggest that yAz stimulates yODC degradation via a similar mechanism of action. We demonstrate that interaction with yAz provokes degradation of yODC by yeast but not by mammalian proteasomes. This differential recognition may serve as a tool for investigating
proteasome
functions.
...
PMID:Yeast antizyme mediates degradation of yeast ornithine decarboxylase by yeast but not by mammalian proteasome: new insights on yeast antizyme. 1808 76
The great majority of
proteasome
substrates are marked for degradation by the attachment of polyubiquitin chains.
Ornithine decarboxylase
is degraded by the
proteasome
in the absence of this modification. We previously showed that this mechanism of degradation was conserved in eukaryotic cells. Here we use a reporter destabilized by mouse
ornithine decarboxylase
to screen non-essential Saccharomyces cerevisiae deletion mutants. We identified novel mutants that affect both ubiquitin-dependent and -independent
proteasome
degradation pathways. YLR021W (IRC25/POC3) and YPL144W (POC4) encode interacting proteins that function in
proteasome
assembly, with putative homologues widespread among eukaryotes. Several additional mutants suffered from defects in
proteasome
-mediated proteolysis. These included mutants in the urmylation pathway of protein modification (but not the Urm1 modifier itself) and the Reg1 regulatory subunit of protein phosphatase 1. Finally, we noted increased rates of
ornithine decarboxylase
turnover in an rpn10Delta mutant in which the degradation of certain ubiquitinated substrates is impaired. Together, these results highlight the utility of a ubiquitin-independent degron in uncovering novel factors affecting general and substrate-specific
proteasome
function.
...
PMID:A genetic screen for Saccharomyces cerevisiae mutants affecting proteasome function, using a ubiquitin-independent substrate. 1826 85
Little is known about the factors that influence the
proteasome
structures in cells and their activity, although this could be highly relevant to cancer therapy. We have previously shown that, within minutes, irradiation inhibits substrate degradation by the 26S
proteasome
in most cell types. Here, we report an exception in U87 glioblastoma cells transduced to express the epidermal growth factor receptor vIII (EGFRvIII) mutant (U87EGFRvIII), which does not respond to irradiation with 26S
proteasome
inhibition. This was assessed using either a fluorogenic substrate or a reporter gene, the
ornithine decarboxylase
degron fused to ZsGreen (cODCZsGreen), which targets the protein to the 26S
proteasome
. To elucidate whether this was due to alterations in
proteasome
composition, we used quantitative reverse transcription-PCR to quantify the constitutive (X, Y, Z) and inducible 20S subunits (Lmp7, Lmp2, Mecl1), and 11S (PA28alpha and beta) and 19S components (PSMC1 and PSMD4). U87 and U87EGFRvIII significantly differed in expression of
proteasome
subunits, and in particular immunosubunits. Interestingly, 2 Gy irradiation of U87 increased subunit expression levels by 16% to 324% at 6 hours, with a coincident 30% decrease in levels of the
proteasome
substrate c-myc, whereas they changed little in U87EGFRvIII. Responses similar to 2 Gy were seen in U87 treated with a proteasome inhibitor, NPI0052, suggesting that
proteasome
inhibition induced replacement of subunits independent of the means of inhibition. Our data clearly indicate that the composition and function of the 26S
proteasome
can be changed by expression of the EGFRvIII. How this relates to the increased radioresistance associated with this cell line remains to be established.
...
PMID:Epidermal growth factor receptor vIII expression in U87 glioblastoma cells alters their proteasome composition, function, and response to irradiation. 1833 49
Targeting of a DNA vaccine encoded protein for degradation via the
proteasome
is attempted since it may enhance the immunogenicity of the vaccine. We have fused HIV-1 reverse transcriptase (RT) to mouse
ornithine decarboxylase
(
ODC
), a protein rapidly degraded by
proteasome
in an ubiquitine-independent fashion, to enhance the introduction of RT into the MHC class I pathway. We also designed a fusion of RT with two short signals from the C-terminus of
ODC
(ODCsig) representing a minimal
proteasome
-targeting moiety of
ODC
(PEST signal). Fusion to
ODC
or
ODC
signal domain led to a marked enhancement of RT degradation. Plasmids encoding RT-
ODC
and RT-ODCsig chimera were used to immunize BALB/c mice. The administration of the plasmids was not associated with autoimmune disease. Moreover, mice receiving RT-ODCsig gene mounted a mixed Th1/Th2 response characterized by the in vitro secretion of IFN-gamma, IL-2, TNF-alpha, IL-4, and IL-10 upon stimulation of splenocytes with RT protein or RT derived peptides. Serum titers of 10(2) to 10(3) were observed in more than 50% of animals in that group, whereas fewer animals mounted an anti-RT response in the RT-
ODC
gene immunized group. Chimeras of the type described here can, therefore, be used in vaccinations aiming to induce HIV-1 RT-specific immune response.
...
PMID:HIV-1 reverse transcriptase artificially targeted for proteasomal degradation induces a mixed Th1/Th2-type immune response. 1846 38
Deposition of misfolded proteins with a polyglutamine expansion is a hallmark of Huntington disease and other neurodegenerative disorders. Impairment of the proteolytic function of the
proteasome
has been reported to be both a cause and a consequence of polyglutamine accumulation. Here we found that the proteasomal chaperones that unfold proteins to be degraded by the
proteasome
but also have non-proteolytic functions co-localized with huntingtin inclusions both in primary neurons and in Huntington disease patients and formed a complex independently of the proteolytic particle. Overexpression of Rpt4 or Rpt6 facilitated aggregation of mutant huntingtin and ataxin-3 without affecting proteasomal degradation. Conversely, reducing Rpt6 or Rpt4 levels decreased the number of inclusions in primary neurons, indicating that endogenous Rpt4 and Rpt6 facilitate inclusion formation. In vitro reconstitution experiments revealed that purified 19S particles promote mutant huntingtin aggregation. When fused to the
ornithine decarboxylase
destabilizing sequence, proteins with expanded polyglutamine were efficiently degraded and did not aggregate. We propose that aggregation of proteins with expanded polyglutamine is not a consequence of a proteolytic failure of the 20S
proteasome
. Rather, aggregation is elicited by chaperone subunits of the 19S particle independently of proteolysis.
...
PMID:Misfolding of proteins with a polyglutamine expansion is facilitated by proteasomal chaperones. 1898 84
The polyamines are small basic molecules essential for cellular proliferation and viability. An autoregulatory circuit that responds to the intracellular level of polyamines regulates their production. In the center of this circuit is a family of small proteins termed antizymes. Antizymes are themselves regulated at the translational level by the level of polyamines. Antizymes bind
ornithine decarboxylase
(
ODC
) subunits and target them to ubiquitin-independent degradation by the 26S
proteasome
. In addition, antizymes inhibit polyamine transport across the plasma membrane via an as yet unresolved mechanism. Antizymes may also interact with and target degradation of other growth-regulating proteins. An inactive
ODC
-related protein termed antizyme inhibitor regulates polyamine metabolism by negating antizyme functions. The ability of antizymes to degrade
ODC
, inhibit polyamine uptake and consequently suppress cellular proliferation suggests that they act as tumor suppressors, while the ability of antizyme inhibitors to negate antizyme function indicates their growth-promoting and oncogenic potential.
...
PMID:Antizyme and antizyme inhibitor, a regulatory tango. 1939 84
The mechanisms that regulate the ubiquitin (Ub)-
proteasome
system's own components, although critically important, are largely unknown. Ub, a principal component of the system, must be maintained at adequate levels to support cellular homeostasis under basal and stressed conditions. It was suggested that Ub is degraded as part of the polyubiquitin chain along with its substrate. Here, we demonstrate in a direct manner that Ub is indeed degraded in a "piggyback" mechanism. Also, it has been shown that monomeric Ub can be rapidly degraded when a C-terminal tail of a minimal length is fused to it. The tail, which may represent the substrate or part of it, or a naturally occurring extended form of Ub, probably allows entry of the protein into the 20S catalytic chamber, while Ub serves as an anchor to the 19S complex. Here, we show that shorter-tailed Ubs, such as UBB(+1), bind to the
proteasome
but because they cannot be efficiently degraded, they inhibit the degradation of other Ub system's substrates such as Myc, p21, Mdm2, and MyoD. The inhibition depends on the ability of the tailed Ubs to be ubiquitinated: their mere binding to the
proteasome
is not sufficient. Interestingly, the inhibition affects only substrates that must undergo ubiquitination for their degradation:
ornithine decarboxylase
that is targeted by the
proteasome
in a Ub-independent manner, is not affected by the short-tailed ubiquitinated Ubs, suggesting it binds to the 19S complex in a site different from that to which ubiquitinated substrates bind.
...
PMID:Ubiquitin degradation with its substrate, or as a monomer in a ubiquitination-independent mode, provides clues to proteasome regulation. 1958 90
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>